Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Bicycle Therapeutics stock price, quote, forecast and news

BCYC
US0887861088
A2PKZC

Price

23.35
Today +/-
-0.22
Today %
-1.06 %
P

Bicycle Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Bicycle Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Bicycle Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Bicycle Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Bicycle Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Bicycle Therapeutics Stock Price History

DateBicycle Therapeutics Price
9/25/202423.35 undefined
9/24/202423.60 undefined
9/23/202423.97 undefined
9/20/202425.41 undefined
9/19/202425.50 undefined
9/18/202424.36 undefined
9/17/202424.41 undefined
9/16/202424.97 undefined
9/13/202427.02 undefined
9/12/202427.24 undefined
9/11/202426.96 undefined
9/10/202427.03 undefined
9/9/202426.36 undefined
9/6/202420.54 undefined
9/5/202420.43 undefined
9/4/202420.59 undefined
9/3/202420.83 undefined
8/30/202421.50 undefined
8/29/202421.66 undefined
8/28/202422.16 undefined

Bicycle Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Bicycle Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bicycle Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bicycle Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bicycle Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bicycle Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bicycle Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bicycle Therapeutics’s growth potential.

Bicycle Therapeutics Revenue, EBIT and net profit per share

DateBicycle Therapeutics RevenueBicycle Therapeutics EBITBicycle Therapeutics Net Income
2029e580.89 M undefined0 undefined252.63 M undefined
2028e332.37 M undefined-59.84 M undefined-79.52 M undefined
2027e124.66 M undefined-245.42 M undefined-319.36 M undefined
2026e47.92 M undefined-280.78 M undefined-280.39 M undefined
2025e32.01 M undefined-253.08 M undefined-247.68 M undefined
2024e42.94 M undefined-211.46 M undefined-219.92 M undefined
202326.98 M undefined-189.35 M undefined-180.66 M undefined
202214.46 M undefined-116.09 M undefined-112.72 M undefined
202111.7 M undefined-65.98 M undefined-66.82 M undefined
202010.39 M undefined-52.54 M undefined-51.01 M undefined
201913.8 M undefined-26.3 M undefined-30.61 M undefined
20187.14 M undefined-21.75 M undefined-21.85 M undefined
20172.06 M undefined-16.21 M undefined-16.26 M undefined
20160 undefined-13.58 M undefined-13.55 M undefined

Bicycle Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0271310111426423247124332580
--250.0085.71-23.0810.0027.2785.7161.54-23.8146.88163.83167.7474.70
--------------
00000000000000
-13-16-21-26-52-65-116-189-211-253-280-245-590
--800.00-300.00-200.00-520.00-590.91-828.57-726.92-502.38-790.63-595.74-197.58-17.77-
-13-16-21-30-51-66-112-180-219-247-280-319-79252
-23.0831.2542.8670.0029.4169.7060.7121.6712.7913.3613.93-75.24-418.99
17.717.717.711.0519.1525.0629.6635.59000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Bicycle Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Bicycle Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
9.467.763.492.1136438.7339.2526.42
0050.25.5120
1.436.36.99.110.919.224.04
00000000
0.50.82.14.95.18911.41
11.371.576.8104.1155.7458.6369.4561.87
0.51.41.84.33.617.832.827.68
00000000
00000000
00000000
00000000
01.131.71.83.48.55.79
0.52.54.865.421.241.333.48
11.87481.6110.1161.1479.8410.7595.34
               
41.896.4122.20.20.30.40.40.55
0.30.81.9195.1249.9567.6601.1883.45
-31.8-48.1-69.9-100.6-151.6-218.4-331.1-511.76
-2,300100-1,800-1,500-3,200-3,400400-1,304
00000000
849.252.493.295.4346.2270.8370.93
1.92.11.91.91.42.76.513.05
1.93.26.96.111.413.72531.25
04.20.10.810.319.821.925.24
00000000
00000000
3.89.58.98.823.136.253.469.54
000014.529.930.330.7
00000000
015.320.38.228.167.456.2124.18
015.320.38.242.697.386.5154.88
3.824.829.21765.7133.5139.9224.41
11.87481.6110.2161.1479.7410.7595.34
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Bicycle Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Bicycle Therapeutics's financial health and stability.

Assets

Bicycle Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Bicycle Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Bicycle Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Bicycle Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-13-16-21-30-51-66-112-180
00001136
000000-43
113-6-72538076
0221113245466
00000222
00000020
-11-1-26-28-17-14-86-60
0-1-1-1-1-2-18-2
0-1-1-1-1-2-18-2
00000000
00000000
0000151500
16572658483056250
16572558623206250
--------
00000000
358-42843302-99187
-11.54-2.53-27.27-30.17-18.99-16.82-105.1-63.56
00000000

Bicycle Therapeutics stock margins

The Bicycle Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bicycle Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bicycle Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bicycle Therapeutics's sales revenue. A higher gross margin percentage indicates that the Bicycle Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bicycle Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bicycle Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bicycle Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bicycle Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bicycle Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bicycle Therapeutics Margin History

Bicycle Therapeutics Gross marginBicycle Therapeutics Profit marginBicycle Therapeutics EBIT marginBicycle Therapeutics Profit margin
2029e0 %0 %43.49 %
2028e0 %-18 %-23.92 %
2027e0 %-196.87 %-256.18 %
2026e0 %-585.88 %-585.08 %
2025e0 %-790.56 %-773.68 %
2024e0 %-492.46 %-512.16 %
20230 %-701.93 %-669.72 %
20220 %-802.84 %-779.53 %
20210 %-563.93 %-571.11 %
20200 %-505.68 %-490.95 %
20190 %-190.58 %-221.81 %
20180 %-304.62 %-306.02 %
20170 %-786.89 %-789.32 %
20160 %0 %0 %

Bicycle Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Bicycle Therapeutics earnings per share therefore indicates how much revenue Bicycle Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bicycle Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bicycle Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bicycle Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bicycle Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bicycle Therapeutics Revenue, EBIT and net profit per share

DateBicycle Therapeutics Sales per ShareBicycle Therapeutics EBIT per shareBicycle Therapeutics Earnings per Share
2029e8.42 undefined0 undefined3.66 undefined
2028e4.82 undefined0 undefined-1.15 undefined
2027e1.81 undefined0 undefined-4.63 undefined
2026e0.69 undefined0 undefined-4.06 undefined
2025e0.46 undefined0 undefined-3.59 undefined
2024e0.62 undefined0 undefined-3.19 undefined
20230.76 undefined-5.32 undefined-5.08 undefined
20220.49 undefined-3.91 undefined-3.8 undefined
20210.47 undefined-2.63 undefined-2.67 undefined
20200.54 undefined-2.74 undefined-2.66 undefined
20191.25 undefined-2.38 undefined-2.77 undefined
20180.4 undefined-1.23 undefined-1.23 undefined
20170.12 undefined-0.92 undefined-0.92 undefined
20160 undefined-0.77 undefined-0.77 undefined

Bicycle Therapeutics business model

Bicycle Therapeutics PLC is a British biotechnology company specializing in the development of innovative drugs for the treatment of cancer and other diseases. The company was founded in 2009 by Sir Greg Winter, John McCafferty, and Sir Tom Blundell. They discovered a new class of molecules called Bicycles, which are small enough to penetrate the human body but large enough to selectively bind to cells and tissues and influence their biological functions. Bicycles are based on a technology called phage display, which allows for the targeted identification and isolation of molecules with specific properties. The business model of Bicycle Therapeutics revolves around using Bicycles as drug candidates for the development of new medications. The company collaborates with leading pharmaceutical and biotechnology companies to jointly develop new therapies, focusing primarily on cancer treatment due to the high demand for targeted therapies in this field. Bicycle Therapeutics has various divisions dedicated to the development of drugs for specific types of cancer. Immunoncology is one such division, which focuses on mobilizing the body's immune system to fight cancer. Another division, Targeted Payloads, concentrates on developing medications that specifically attack and destroy cancer cells. The company offers a range of products developed based on Bicycles, including therapeutic antibodies that selectively target and destroy cancer cells, as well as diagnostics for the early detection and diagnosis of cancer. One example of Bicycle Therapeutics' product is BT1718, a therapeutic antibody that specifically targets the membrane protein 5 (MP5). MP5 is expressed on the surface of various cancer cells and is therefore a promising target for cancer therapy. BT1718 has shown promising results in clinical studies involving patients with various types of cancer. Another example is BT5528, a targeted payload that targets the EphA2 receptor. EphA2 is expressed on the surface of different cancer cells and plays a crucial role in tumor progression. BT5528 is a molecule that specifically binds to EphA2 and releases a payload that attacks and destroys cancer cells. The product is currently in clinical development. Overall, Bicycle Therapeutics is a promising biotechnology company specializing in the development of innovative drugs for the treatment of cancer and other diseases. The company has a unique technology platform and collaborates with leading pharmaceutical and biotechnology companies to develop new therapies. With products like BT1718 and BT5528, Bicycle Therapeutics has already achieved promising results and remains an important player in the field of cancer therapy. Bicycle Therapeutics is one of the most popular companies on Eulerpool.com.

Bicycle Therapeutics SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Bicycle Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Bicycle Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Bicycle Therapeutics shares outstanding

The number of shares was Bicycle Therapeutics in 2023 — This indicates how many shares 35.592 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bicycle Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bicycle Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bicycle Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bicycle Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Bicycle Therapeutics.

Bicycle Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.12 -0.77  (31.27 %)2024 Q2
3/31/2024-1.27 -0.62  (51.12 %)2024 Q1
12/31/2023-1.26 -1.16  (7.8 %)2023 Q4
9/30/2023-1.19 -1.26  (-5.45 %)2023 Q3
6/30/2023-1.32 -1.41  (-6.88 %)2023 Q2
3/31/2023-1.09 -1.3  (-18.78 %)2023 Q1
12/31/2022-1.08 -1.01  (6.46 %)2022 Q4
9/30/2022-0.91 -0.96  (-5.91 %)2022 Q3
6/30/2022-0.87 -0.9  (-3.99 %)2022 Q2
3/31/2022-0.7 -0.93  (-33.76 %)2022 Q1
1
2
3

Bicycle Therapeutics list of shareholders

%
Name
Stocks
Change
Date
5.37324 % Paradigm BioCapital Advisors LP3,707,00164,69412/31/2023
5.05944 % Deep Track Capital LP3,490,506012/31/2023
2.82360 % Jefferies LLC1,948,000012/31/2023
2.53868 % Cambridge Innovation Capital Jersey Ltd1,751,43704/20/2023
2.39211 % Tybourne Capital Management (HK) Limited1,650,320368,50012/31/2023
2.24739 % First Light Asset Management, LLC1,550,471-520,38212/31/2023
2.22641 % Armistice Capital LLC1,536,000536,00012/31/2023
10.17129 % Baker Bros. Advisors LP7,017,1764,966,9964/16/2024
1.45606 % Polar Capital LLP1,004,535-6,96512/31/2023
1.32962 % Westfield Capital Management Company, L.P.917,304917,30412/31/2023
1
2
3
4
5
...
10

Bicycle Therapeutics Executives and Management Board

Mr. Kevin Lee55
Bicycle Therapeutics Chief Executive Officer, Executive Director (since 2015)
Compensation 8.63 M
Mr. Alistair Milnes49
Bicycle Therapeutics Chief Operating Officer
Compensation 5.98 M
Dr. Michael Skynner54
Bicycle Therapeutics Chief Technology Officer
Compensation 3.07 M
Mr. Pierre Legault62
Bicycle Therapeutics Non-Executive Chairman of the Board
Compensation 1.56 M
Dr. Nigel Crockett58
Bicycle Therapeutics Chief Business Officer
Compensation 1.4 M
1
2
3

Most common questions regarding Bicycle Therapeutics

What values and corporate philosophy does Bicycle Therapeutics represent?

Bicycle Therapeutics PLC represents values of innovation, collaboration, and patient-centricity. As a biotechnology company, Bicycle Therapeutics focuses on developing novel therapeutics using its proprietary Bicycle Drug Conjugate (BDC) platform. The company aims to address unmet medical needs and improve patient outcomes through the targeted delivery of drugs. Bicycle Therapeutics emphasizes scientific excellence, fostering partnerships, and translating scientific discoveries into potential therapies. By leveraging its unique technology, the company strives to develop drugs with enhanced efficacy and reduced side effects. Bicycle Therapeutics PLC is committed to advancing therapeutics that have the potential to transform the lives of patients and contribute to the advancement of medical science.

In which countries and regions is Bicycle Therapeutics primarily present?

Bicycle Therapeutics PLC primarily operates in the United Kingdom and the United States. The company is based in Cambridge, UK, and its main focus is on developing a new class of medicines using its unique bicyclic peptide (Bicycle®) technology. With its presence in the UK and the US, Bicycle Therapeutics PLC remains dedicated to advancing its innovative therapeutic platform and collaborating with various partners to enhance the treatment options for patients globally.

What significant milestones has the company Bicycle Therapeutics achieved?

Bicycle Therapeutics PLC has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in May 2019, raising substantial funds to support its ongoing research and development efforts. Bicycle Therapeutics also entered into several strategic collaborations and partnerships, including a collaboration with AstraZeneca in 2016 to develop bicycle-based therapeutics in oncology and an agreement with Bioverativ in 2018 for the discovery and development of novel therapies for hemophilia and sickle cell disease. These partnerships have further strengthened the company's position in the biotechnology industry. Additionally, Bicycle Therapeutics achieved regulatory milestones with the initiation of clinical trials for its drug candidates, demonstrating progress towards potential commercialization.

What is the history and background of the company Bicycle Therapeutics?

Bicycle Therapeutics PLC is a leading clinical-stage biopharmaceutical company specializing in the development of bicyclic peptides. Founded in 2009 in Cambridge, England, Bicycle Therapeutics has emerged as a pioneer in the field of peptide-based therapeutics. The company's proprietary technology allows for the precise targeting of disease-related proteins, offering a potential breakthrough in the treatment of various diseases, including cancer. Bicycle Therapeutics has established strategic partnerships with renowned pharmaceutical companies, further validating its innovative approach. With a strong commitment to research and development, the company continues to advance its pipeline and explore new applications for its unique technology platform.

Who are the main competitors of Bicycle Therapeutics in the market?

The main competitors of Bicycle Therapeutics PLC in the market include large pharmaceutical companies specializing in the development of oncology drugs, such as Roche Holding AG, Novartis AG, and AstraZeneca plc. These companies compete with Bicycle Therapeutics in the field of targeted therapy using innovative bicyclic peptides. Additionally, other biotechnology companies focusing on cancer therapeutics, such as Amgen Inc., Celgene Corporation, and Gilead Sciences Inc., pose competition in the market. Bicycle Therapeutics PLC differentiates itself through its proprietary bicyclic peptide platform and strategic collaborations with industry leaders.

In which industries is Bicycle Therapeutics primarily active?

Bicycle Therapeutics PLC is primarily active in the biotechnology and pharmaceutical industries. As a leading company in the field, Bicycle Therapeutics PLC focuses on developing innovative therapeutics based on its proprietary bicyclic peptide platform. Through its extensive research and development efforts, the company aims to address unmet medical needs in various therapeutic areas, including oncology and respiratory diseases. With its cutting-edge technology and strategic collaborations, Bicycle Therapeutics PLC is committed to advancing the next generation of targeted therapies to improve patient outcomes and revolutionize the treatment landscape.

What is the business model of Bicycle Therapeutics?

Bicycle Therapeutics PLC is a biotechnology company specializing in the development of novel therapeutics using its proprietary bicyclic peptide (Bicycle) platform. The company's business model focuses on discovering and developing highly selective and potent Bicycle-based drugs to target diseases with high unmet medical needs. Bicycle Therapeutics leverages its unique platform to create precise and targeted therapies that have the potential to address a wide range of diseases, including oncology and inflammatory conditions. By combining the benefits of large molecules with the properties of small molecules, Bicycle Therapeutics aims to deliver innovative and effective treatments for patients worldwide.

What is the P/E ratio of Bicycle Therapeutics 2024?

The Bicycle Therapeutics P/E ratio is -3.78.

What is the P/S ratio of Bicycle Therapeutics 2024?

The Bicycle Therapeutics P/S ratio is 19.35.

What is the AlleAktien quality score of Bicycle Therapeutics?

The AlleAktien quality score for Bicycle Therapeutics is 4/10.

What is the revenue of Bicycle Therapeutics 2024?

The expected Bicycle Therapeutics revenue is 42.94 M USD.

How high is the profit of Bicycle Therapeutics 2024?

The expected Bicycle Therapeutics profit is -219.92 M USD.

What is the business model of Bicycle Therapeutics

Bicycle Therapeutics is a biotech company that focuses on the development of drugs based on bicycle technology. This innovative method allows for more targeted and effective modification of proteins compared to conventional methods. The company's business model revolves around the development and marketing of bicycle-based drugs in various medical fields. They specialize in oncology, developing drugs that selectively attack and destroy cancer cells. They also work in immunology to influence and support the immune system, such as combating autoimmune diseases or assisting in cancer immunotherapy. Additionally, Bicycle Therapeutics develops drugs for various indications, including neurology, infectious diseases, and cardiology. Collaborations with pharmaceutical and biotech companies are a crucial part of Bicycle Therapeutics' business model. Overall, the company offers a wide range of products using their innovative bicycle technology and aims to bring effective and targeted drugs to market through partnerships.

What is the Bicycle Therapeutics dividend?

Bicycle Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Bicycle Therapeutics pay dividends?

The dividend cannot currently be calculated for Bicycle Therapeutics or the company does not pay out a dividend.

What is the Bicycle Therapeutics ISIN?

The ISIN of Bicycle Therapeutics is US0887861088.

What is the Bicycle Therapeutics WKN?

The WKN of Bicycle Therapeutics is A2PKZC.

What is the Bicycle Therapeutics ticker?

The ticker of Bicycle Therapeutics is BCYC.

How much dividend does Bicycle Therapeutics pay?

Over the past 12 months, Bicycle Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bicycle Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bicycle Therapeutics?

The current dividend yield of Bicycle Therapeutics is .

When does Bicycle Therapeutics pay dividends?

Bicycle Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bicycle Therapeutics?

Bicycle Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Bicycle Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bicycle Therapeutics located?

Bicycle Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bicycle Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bicycle Therapeutics from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Bicycle Therapeutics pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Bicycle Therapeutics in the year 2023?

In the year 2023, Bicycle Therapeutics distributed 0 USD as dividends.

In which currency does Bicycle Therapeutics pay out the dividend?

The dividends of Bicycle Therapeutics are distributed in USD.

All fundamentals about Bicycle Therapeutics

Our stock analysis for Bicycle Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bicycle Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.